Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

NMRA stock hub

Neumora Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

NMRAis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

334.3M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

NMRA

In the news

Latest news · NMRA

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROEn/a

P25 -105.6P50 -46.5P75 -3.1

ROIC-70.2

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All NMRA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

157

Groups with data

Currency

USD

Showing 157 of 157 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001885522
Company name	Neumora Therapeutics, Inc.
Country	United States
Country code	US
Cusip	640979100
Employees	96
Employees Change	-14%
Employees Change Percent	-12.73
Enterprise value	$206.8M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2023-09-15
Isin	US6409791000
Last refreshed	2026-05-10
Market cap	$334.3M
Market cap category	Small-Cap
Price	$1.83
Price currency	USD
Sector	Healthcare
Sic	2836
Symbol	NMRA
Website	https://www.neumoratx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-66.52%
P/B ratio	3.07x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-222.4M
Net Income Growth Quarters	1%
Net Income Growth Years	1%
Profit Per Employee	$-2.3M
Roa5y	-31.61
Roe5y	-70.61
ROIC	-70.23

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	180.79%
EPS Growth Quarters	4
EPS Growth Years	3
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Cash	$182.5M
Debt	$55M
Debt Equity	$0.53
Equity	$103.9M
Interest Coverage	-42.99
Net Cash	$127.5M
Net Cash By Market Cap	$38.14
Net Cash Growth	-48.67%
Net Debt Equity	$-1.23
Tangible Book Value	$103.9M
Tangible Book Value Per Share	$0.6
WACC	19.09

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-4.83%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	180.59%
200-day SMA	2.2
50-day SMA	2.46
50-day SMA vs 200-day SMA	50over200
All Time High	21
All Time High Change	-91.29%
All Time High Date	2024-03-08
All Time Low	0.61
All Time Low Change	199.51%
All Time Low Date	2025-05-14
ATR	0.21
Beta	3.05
Beta1y	2.14
Beta2y	2.36
Ch YTD	2.24
High	1.98
High52	3.65
High52 Date	2026-02-18
High52ch	-49.86%
Low	1.76
Low52	0.61
Low52 Date	2025-05-14
Low52ch	199.51%
Ma50ch	-25.58%
Premarket Change Percent	2.06
Premarket Price	$1.98
Premarket Volume	1,988
Price vs 200-day SMA	-16.67%
RSI	32.51
RSI Monthly	38.73
RSI Weekly	42.54
Sharpe ratio	1.44x
Sortino ratio	2.78
Total Return	-4.83%
Tr YTD	2.24
Tr1m	-14.08%
Tr1w	-25%
Tr3m	-13.68%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	8
Analyst Count Top	5
Analyst Price Target Top	$8.75
Analyst Ratings	Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-0.31
Operating Income	$-218.1M
Price target	$7.5
Price Target Change	$310
Price Target Change Top	$378

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	105,204,003%
Float Percent	57.59%
Shares Insiders	4.53%
Shares Institutions	36.09%
Shares Out	182,688,076
Shares Qo Q	6.74%
Shares Yo Y	4.83%
Short Float	4.25%
Short Ratio	3.78
Short Shares	2.45

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	1,554,139.3x
Bv Per Share	0.6
Ch1m	-14.08
Ch1w	-25
Ch1y	180.6
Ch3m	-13.68
Ch6m	-28.52
Change	-5.67%
Change From Open	-7.11
Close	1.94
Days Gap	1.55
Depreciation Amortization	103,000
Dollar Volume	3,897,102.1
Earnings Date	2026-05-07
Earnings Time	bmo
EBIT	$-218.1M
EBITDA	$-218M
EPS	$-1.33
F Score	0
Fiscal Year End	December
Founded	2,019
Income Tax	$55,000
Ipr	-89.24
Iprfo	-88.91
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-30
Ma150	2.36
Ma150ch	-22.29%
Ma20	2.2
Ma20ch	-16.7%
Next Earnings Date	2026-08-05
Open	1.97
Optionable	Yes
Position In Range	33.33
Post Close	1.83
Postmarket Change Percent	0.05
Postmarket Price	$1.83
Pre Close	1.94
Price Date	2026-05-08
Ptbv Ratio	3.22
Relative Volume	1.37x
Tr6m	-28.52%
Us State	Massachusetts
Volume	2,129,564

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does NMRA pay a dividend?

Capital-return profile for this ticker.

Performance

NMRA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns NMRA?

Insider, institutional, and short-interest positioning.

Institutional ownership

+36.1%

Float: +57.6% of shares outstanding

Insider ownership

+4.5%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

NMRA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

32.5

Neutral momentum band

Price vs 200-day MA

-16.7%

50/200-day relationship not available

Beta (5Y)

3.05

More volatile than the market

Sharpe ratio

1.44

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About NMRA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current NMRA stock rating?

Neumora Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full NMRA analysis?

The full report lives at /stocks/NMRA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for NMRA?

The latest report frames NMRA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the NMRA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.